EUVIMEDEUVIMED entdecken
Crossref

Effect of pre‐emptive rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium

Isa F Ashoor iD, Samhar Al-Akash iD, Sarah Kizilbash iD, Asha Moudgil iD, Dechu Puliyanda iD, Saritha Ranabothu iD, Yi Shi iD, Vikas Dharnidharka iD

Pediatric Transplantation · 2024

DOI: 10.1111/petr.14743 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Isa F Ashoor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Kidney Transplantation, Nephrology, Lymphoproliferative Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are scant data on the effect of rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplant recipients with EBV DNAemia.

Methods

Kidney transplant recipients with EBV DNAemia treated with rituximab to prevent PTLD between 7/1999 and 7/2019 at five pediatric centers were included. Those with confirmed PTLD at the onset of rituximab were excluded. Primary outcomes included percentage change in EBV DNAemia and occurrence of PTLD post rituximab.

Results

Twenty‐six pediatric kidney transplant recipients were included. Median age at transplant was 4 years (IQR 2.1–10.3). EBV DNA load monitoring by qPCR was performed at 1–3 month intervals. EBV DNAemia onset occurred at a median of 73 days post‐transplant (IQR 52–307), followed by DNAemia peak at a median of 268 days (IQR 112–536). Rituximab was administered at a median of 9 days post peak (IQR 0–118). Rituximab regimens varied; median dose 375 mg/m 2 (IQR 375–439) weekly for 1–4 doses per course. Following rituximab, EBV DNA load decreased to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsKidney TransplantationNephrologyLymphoproliferative DisordersHumansChildChild, PreschoolRituximabHerpesvirus 4, HumanDNA, ViralTransplant RecipientsViral Load

Stichwörter der Autor:innen

Epstein–Barr viruskidney transplantpediatricspost‐transplant lymphoproliferative disorderrituximab

Substanzen

RituximabDNA, Viral

Autor:innen und Institutionen

  • Division of Nephrology, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Nephrology, Department of Pediatrics, The University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
  • Division of Nephrology, Department of Pediatrics, University of Minnesota Children's Hospital, Minneapolis, Minnesota, USA.
  • Division of Nephrology, Department of Pediatrics, Children's National Medical Center, Washington, DC, USA.
  • Division of Nephrology, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Division of Nephrology, Department of Pediatrics, Arkansas Children's Hospital, Little Rock, Arkansas, USA.

ORCID-Profile: Isa F Ashoor, Samhar Al-Akash, Sarah Kizilbash, Asha Moudgil, Dechu Puliyanda, Saritha Ranabothu, Yi Shi, Vikas Dharnidharka

Zitieren

APA

Ashoor, I. F., Al-Akash, S., Kizilbash, S., Moudgil, A., Puliyanda, D., Ranabothu, S., Shi, Y., & Dharnidharka, V. (2024). Effect of pre‐emptive rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium. Pediatric Transplantation. https://doi.org/10.1111/petr.14743

Vancouver

Ashoor IF, Al-Akash S, Kizilbash S, Moudgil A, Puliyanda D, Ranabothu S, et al. Effect of pre‐emptive rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium. Pediatric Transplantation. 2024. doi:10.1111/petr.14743

BibTeX
@article{Ashoor2024,
  author = {Ashoor, Isa F and Al-Akash, Samhar and Kizilbash, Sarah and Moudgil, Asha and Puliyanda, Dechu and Ranabothu, Saritha and Shi, Yi and Dharnidharka, Vikas},
  title = {Effect of pre‐emptive rituximab on EBV DNA levels and prevention of post‐transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium},
  journal = {Pediatric Transplantation},
  year = {2024},
  doi = {10.1111/petr.14743}
}
Kostenlos starten →